...
机译:当评估参数的不确定性足够的:达沙替尼和NilotinibImatinib-Resistant慢性骨髓性白血病
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA;
European Medicines Agency; National Institute for Health and Clinical Excellence; ImatinibUnited States National Institutes of HealthMyeloid leukemiaPharmaceutical Preparationsparameter uncertaintySprycelnilotinib;
机译:Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
机译:Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib
机译:Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers
机译:KE吗arc model parameters evaluation
机译:Dasatinib与Nilotinib对卡塔尔慢性骨髓白血病慢性阶段的前期治疗:成本效益分析
机译:Validação do Escore de Risco do EBmT em 1.084 pacientes portadores de leucemia mielóide crônica submetidos ao transplante alogênico de células precursoras hematopoiéticas no Brasil allogeneic hematopoietic stem cell transplantation - EBmT risk score validation in 1084 chronic myeloid leukemia patients transplanted in Brazil